High Intensity Interval Training
Behavioral9 months of high intensity interval based aerobic exercise (3 times/week)
NCT Number: NCT01796379
Compared to end-stage heart failure, a patient's situation is usually greatly improved after a heart transplant (HTx), but the exercise capacity remains sub-normal, also long-term, ranging from 50 to 70% in most studies. While effective rehabilitation, including regular exercise, is considered an effective tool of improving health related quality of life (HRQoL) and prognosis of cardiac patients in general, the knowledge about and the effect of different rehabilitation programs among HTx recipients is limited. Exercise training is considered one of the most central parts in rehabilitation, but the mode of exercise used in different studies varies considerably. It is documented that high intensity interval training (HIT) has superior effects compared to training with moderate intensity in cardiac and heart failure patients. In contrast, HTx recipients have a denervated heart, and HIT had been considered unphysiological. However, the investigators have recently demonstrated highly beneficial effects on exercise capacity, muscle strength, body composition, reduced progression of cardiac allograft vasculopathy and HRQoL among long-term HTx recipients. In the present study the investigators want to test the hypothesis that systematic aerobic exercise with high intensity improve exercise capacity also in newly transplanted recipients, and secondarily that it gives favourable effects on the heart, peripheral circulation and a better HRQoL.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Copenhagen University Hospital, Copenhagen, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
9 months of high intensity interval based aerobic exercise (3 times/week)
Other names: Regular exercise training offered to all heart transplant recipients (usual care)
Time frame: Baseline to one year
Change in ml/kg/min
Time frame: Baseline to one year
Change measured in Newtonmeter and Joule
Time frame: Baseline to one year
Change measured by intravascular ultrasound; change in maximum intimal thickness, total atheroma volume, percent atheroma volume and virtual histology.
Time frame: Baseline to one year
Change in heart rate response, including changes in minimum and maximum heart rate and changes in chronotropic response index.
Time frame: Baseline to one year
Change in echocardiographic parametres such as stroke volume, cardiac index and ejection fraction.
Time frame: Baseline to one year
Change in endothelial function measured by flow mediated dilatation and EndoPat
Time frame: Baseline to one year
Neuroendocrine, inflammatory and immunological biomarkers.
Time frame: Baseline to one year
Change measured on visual analogue scales and questionnaires
Time frame: Baseline to 3 years follow-up
Measured by number of serious adverse effects related to the intervention
Time frame: Baseline to 3 years follow-up
Long-term effects will be measured by all outcomes listed above, including number of serious adverse effects.
Oslo University Hospital
Other
Acronym: HITTS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07132554
Heart Transplant Recipients
View Trial DetailsNCT01914406
Heart Transplant Recipients
Copenhagen, Denmark
View Trial DetailsNCT03662789
Heart Transplant Recipients, Iron Deficiencies
Oslo, Norway
View Trial DetailsNCT02077764
Behavior, Heart Transplant Recipients
Aarhus, Aarhus N, Denmark
View Trial Details